Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB015 vs Secukinumab in Moderate-Severe Chronic Plaque Psoriasis
NCT06398652Phase 3Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Taizhou Mabtech Pharmaceutical. Started Aug 2024; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06398652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398652.